| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Amortization of operating lease right-of-use assets | - | 399 |
| Investment loss from investment in eton pharmaceuticals | - | 0 |
| Net loss | -11,765 | -12,785 |
| Depreciation and amortization of property, plant and equipment and software development costs | 1,451 | 961 |
| Amortization of intangible assets | 12,676 | 8,452 |
| Non-cash lease expense | 583 | - |
| Deferred income tax | - | 0 |
| Provision for (recovery of) credit losses | 548 | 340 |
| Amortization of debt issuance costs and debt discount | 3,692 | 2,564 |
| Loss on extinguishment of debt | -7,750 | - |
| Stock-based compensation | 8,702 | 5,431 |
| Accounts receivable | -38,225 | -37,211 |
| Inventories | 2,132 | 850 |
| Prepaid expenses and other current assets | -2,449 | -3,776 |
| Accounts payable, accrued expenses, accrued rebates and copay assistance | -27,049 | -24,009 |
| Accrued payroll and related liabilities | 22 | -2,672 |
| Deferred revenue and customer deposits | 301 | 47 |
| Net cash provided by (used in) operating activities | 35,453 | 18,865 |
| Investment in patent and trademark assets | 22 | 169 |
| Net proceeds on sale of investment in eton pharmaceuticals | - | 0 |
| Purchase of product rights and related patents | 162 | - |
| Purchases of property, plant and equipment | 546 | 336 |
| Net cash (used in) provided by investing activities | -730 | -505 |
| Proceeds from new debt, net of costs | 244,375 | - |
| Payment of debt issuance costs | 1,581 | 0 |
| Repayment of notes payable, including exit costs | 230,901 | - |
| Payment of payroll taxes upon vesting of psus, rsus and exercise of stock options | 19,860 | 12,769 |
| Proceeds from exercise of stock options | 287 | 125 |
| Net cash used in financing activities | -7,680 | -12,644 |
| Net change in cash and cash equivalents | 27,043 | 5,716 |
| Cash and cash equivalents at beginning of period | 47,247 | - |
| Cash and cash equivalents at end of period | 74,290 | - |
HARROW, INC. (HROW)
HARROW, INC. (HROW)